STOCK TITAN
  1. Home
  2. Sec-filings
  3. BLTE
  4. [Form 4] BELITE BIO, INC Insider Trading Activity

Belite Bio (BLTE) CSO sells 1,000 ADSs in Rule 10b5-1 trades

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Belite Bio, Inc. Chief Scientific Officer Nathan L. Mata reported open-market sales of 1,000 American depositary shares (ADSs) on May 5, 2026. The ADSs were sold in multiple trades at prices ranging from about $153.92 to $158.11.

The filing states these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, indicating they were scheduled in advance. Following the transactions, Mata directly holds 2,546 ADSs of Belite Bio.

Positive

  • None.

Negative

  • None.

Insights

Routine 10b5-1 insider sales of 1,000 ADSs with modest remaining stake.

Belite Bio's Chief Scientific Officer, Nathan L. Mata, sold 1,000 American depositary shares in six open-market trades on May 5, 2026. Sale prices ranged from roughly $153.92 to $158.11, reflecting normal trading activity within a tight band.

The filing notes these transactions occurred under a pre-established Rule 10b5-1 trading plan adopted on December 10, 2025, suggesting the timing was pre-scheduled rather than discretionary. After the sales, Mata still holds 2,546 ADSs directly, so this appears as a limited, planned liquidity event rather than a wholesale exit.

Insider MATA NATHAN L.
Role Chief Scientific Officer
Sold 1,000 shs ($156K)
Type Security Shares Price Value
Sale American depositary share 120 $153.9217 $18K
Sale American depositary share 363 $154.4433 $56K
Sale American depositary share 173 $155.4771 $27K
Sale American depositary share 121 $156.5292 $19K
Sale American depositary share 155 $157.2897 $24K
Sale American depositary share 68 $158.11 $11K
Holdings After Transaction: American depositary share — 2,546 shares (Direct, null)
Footnotes (1)
  1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025. Represents the weighted average price of shares sold at prices that ranged from $153.92 to $153.93. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $154.01 to $154.955. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $155.04 to $155.91. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $156.005 to $156.94. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $157.035 to $157.99. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
Total ADSs sold 1,000 ADSs Open-market sales on May 5, 2026
Post-transaction holdings 2,546 ADSs Direct ownership after sales
Trade price example 1 $158.11 per ADS Sale of 68 ADSs
Trade price example 2 $157.2897 per ADS Sale of 155 ADSs
Trade price example 3 $153.9217 per ADS Sale of 120 ADSs
Number of sale transactions 6 transactions All on May 5, 2026
American depositary share financial
"Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer."
An American Depositary Share (ADS) is a U.S.-listed certificate that represents a specified number of shares in a foreign company, held by a custodian bank; it works like a receipt that allows U.S. investors to buy and trade foreign equity on American exchanges without dealing with another country’s markets. Investors care because ADSs make foreign stocks easier to access, improve liquidity and settlement in dollars, and can affect dividend payments, voting rights and regulatory oversight compared with buying the underlying foreign shares directly.
Rule 10b5-1 trading plan regulatory
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"Represents the weighted average price of shares sold at prices that ranged from $153.92 to $153.93."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Form 4 regulatory
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025."
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MATA NATHAN L.
(Last)(First)(Middle)
7708 MARKER ROAD
(Street)
SAN DIEGO CALIFORNIA 92130
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Scientific Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
American depositary share(1)05/05/2026S(2)120D$153.9217(3)2,546D
American depositary share(1)05/05/2026S(2)363D$154.4433(4)2,183D
American depositary share(1)05/05/2026S(2)173D$155.4771(5)2,010D
American depositary share(1)05/05/2026S(2)121D$156.5292(6)1,889D
American depositary share(1)05/05/2026S(2)155D$157.2897(7)1,734D
American depositary share(1)05/05/2026S(2)68D$158.111,666D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer.
2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025.
3. Represents the weighted average price of shares sold at prices that ranged from $153.92 to $153.93. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
4. Represents the weighted average price of shares sold at prices that ranged from $154.01 to $154.955. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
5. Represents the weighted average price of shares sold at prices that ranged from $155.04 to $155.91. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
6. Represents the weighted average price of shares sold at prices that ranged from $156.005 to $156.94. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
7. Represents the weighted average price of shares sold at prices that ranged from $157.035 to $157.99. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
/s/ Nathan L. Mata05/06/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Belite Bio (BLTE) report in this Form 4?

Nathan L. Mata, Chief Scientific Officer of Belite Bio, reported selling 1,000 American depositary shares in open-market trades. The sales occurred on May 5, 2026 at prices in the mid-$150s, according to the Form 4 filing.

At what prices did the Belite Bio (BLTE) insider sell shares?

The Chief Scientific Officer sold Belite Bio ADSs at prices ranging from about $153.92 to $158.11. Individual trades used weighted average prices within narrow bands, as detailed in the Form 4 footnotes for each transaction.

How many Belite Bio (BLTE) shares does the insider hold after these sales?

After the reported sales, Chief Scientific Officer Nathan L. Mata directly holds 2,546 American depositary shares of Belite Bio. This post-transaction figure comes from the Form 4 and reflects his remaining direct ownership position.

Were the Belite Bio (BLTE) insider sales under a Rule 10b5-1 plan?

Yes. The Form 4 states the sales were executed under a Rule 10b5-1 trading plan adopted by Nathan L. Mata on December 10, 2025. Such pre-arranged plans schedule trades in advance to reduce timing-related concerns.

What type of security did the Belite Bio (BLTE) insider sell?

The transactions involved American depositary shares (ADSs) of Belite Bio. A footnote explains that each ADS represents one ordinary share of the issuer, with a par value of US$0.0001 per ordinary share.